Clinical Trials
18 trialsNCT02489318 2026-06-05
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT03767244 2026-06-05
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04108208 2026-06-05
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT05884398 2026-06-05
LIBERTAS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05404139 2026-06-04
DIRECT
University Health Network, Toronto
Phase 2 Recruiting
NCT03419234 2026-06-03
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05477823 2026-06-02
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
University of Wisconsin, Madison
Phase EARLY_PHASE1 Active not recruiting
NCT07393867 2026-05-29
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Recruiting
NCT07570979 2026-05-28
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Novartis
Phase 1 Recruiting
NCT03388619 2026-05-27
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04126070 2026-05-27
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06274047 2026-05-20
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT07340541 2026-05-20
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06661122 2026-05-19
HAYATE
Bayer
Recruiting
NCT06952803 2026-05-19
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT07477626 2026-05-19
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04947254 2026-05-15
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07476001 2026-05-15
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting